The pharmacokinetics and pharmacodynamics of pulmonary Mycobacterium avium complex disease treatment.
about
Diagnosis and Treatment of Nontuberculous Mycobacterial Lung DiseaseDiagnosis and Treatment of Nontuberculous Mycobacterial Lung Disease: Clinicians' PerspectivesUS Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosisSeeing a Mycobacterium-Infected Cell in Nanoscale 3D: Correlative Imaging by Light Microscopy and FIB/SEM TomographyPulmonary Disease Due to Nontuberculous Mycobacteria: Current State and New InsightsIn Vitro activities of combinations of rifampin with other antimicrobials against multidrug-resistant Acinetobacter baumannii.Experimental Reactivation of Pulmonary Mycobacterium avium Complex Infection in a Modified Cornell-Like Murine Model.Analysis of drug treatment outcome in clarithromycin-resistant Mycobacterium avium complex lung disease.Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry for Combined Species Identification and Drug Sensitivity Testing in Mycobacteria.In vitro synergy between clofazimine and amikacin in treatment of nontuberculous mycobacterial disease.The Challenge of Pulmonary Nontuberculous Mycobacterial Infection.Clofazimine Prevents the Regrowth of Mycobacterium abscessus and Mycobacterium avium Type Strains Exposed to Amikacin and Clarithromycin.Amikacin Pharmacokinetics/Pharmacodynamics in a Novel Hollow-Fiber Mycobacterium abscessus Disease Model.Azithromycin Dose To Maximize Efficacy and Suppress Acquired Drug Resistance in Pulmonary Mycobacterium avium DiseaseTreatment of refractory Mycobacterium avium complex lung disease with a moxifloxacin-containing regimenFailure of the Amikacin, Cefoxitin, and Clarithromycin Combination Regimen for Treating Pulmonary Mycobacterium abscessus Infection.Peak Plasma Concentration of Azithromycin and Treatment Responses in Mycobacterium avium Complex Lung DiseasePulmonary Deposition and Elimination of Liposomal Amikacin for Inhalation and Effect on Macrophage Function after Administration in RatsClinical Characteristics, Treatment Outcomes, and Resistance Mutations Associated with Macrolide-Resistant Mycobacterium avium Complex Lung DiseaseLack of adherence to evidence-based treatment guidelines for nontuberculous mycobacterial lung diseaseUpdate in tuberculosis and nontuberculous mycobacterial disease 2012.Mycobacterium avium complex (MAC) Immune Reconstitution Syndrome (IRIS) With Reduced Susceptibility to Ethambutol in an HIV-Infected Patient.Update on nontuberculous mycobacterial infections in solid organ and hematopoietic stem cell transplant recipients.Antimicrobial treatment of non-cystic fibrosis bronchiectasis.Drug susceptibility testing of nontuberculous mycobacteria.Human infections due to nontuberculous mycobacteria: the infectious diseases and clinical microbiology specialists' point of view.Antibiotic treatment for nontuberculous mycobacterial lung disease.Rifabutin: where do we stand in 2016?Time-kill kinetics of slowly growing mycobacteria common in pulmonary disease.Time-kill kinetics of antibiotics active against rapidly growing mycobacteria.Treatment of Non-Tuberculous Mycobacterial Lung Disease.Dynamics of immune effector mechanisms during infection with Mycobacterium avium in C57BL/6 mice.Emergence of mmpT5 Variants during Bedaquiline Treatment of Mycobacterium intracellulare Lung DiseaseNon-Tuberculous Mycobacteria: Classification, Diagnostics, and Therapy.Efficacy of clarithromycin and ethambutol for Mycobacterium avium complex pulmonary disease. A preliminary study.Treatment of pulmonary Mycobacterium avium complex infections: do drug levels matter?Are guidelines on the management of non-tuberculous mycobacteria lung infections respected and what are the consequences for patients? A French retrospective study from 2007 to 2014.First you have to row a little boat.Treatment of Mycobacterium avium-intracellulare complex: a great leap forward.Impact of Clofazimine Dosing on Treatment-Shortening of the First-Line Regimen in a Mouse Model of Tuberculosis.
P2860
Q26748674-A038A898-8F2E-4CF0-959F-67354023EC48Q26749480-792C3FED-38CB-497F-9C3A-C5C2275C97E6Q26775974-4583C2E7-DB86-4AD1-9374-BF9D759CE64EQ27301102-8DCA9E3A-82A7-43AF-8D86-AE5CD6C8E4D7Q28087593-F5153CEB-AE47-42D6-A55C-3597F852A6B2Q35076951-8CB9D8CB-57E2-43A9-ACE0-F9167C73F84AQ35787739-CBC23029-C726-4923-B27B-1B7604AC94CEQ35906474-CCB6451A-0DAF-40F8-AFBA-1DD1C65F6C5BQ36230810-DB7FF05B-4F84-4B48-A842-CCCBB2FE3E68Q36396162-6B263DF9-5D57-41EE-92CC-D7ACBA2CE4F4Q36567746-2F9A7DB7-F7D1-4989-9A2A-12D2E31E1CA8Q36571826-6320B4D6-94C3-4612-BC23-D04DD8C4E7E4Q36644647-E29694A9-514C-472C-811E-D42FCEB0C311Q36730088-78575FA7-C7F4-41E9-912A-F951769017A3Q36785858-68C7C93D-A09B-4A75-84FD-438D6FB98641Q37287641-677C107C-C466-481A-8DA5-61EAB7D36DEFQ37287653-832FD84C-376B-446E-AC97-6CB50B032206Q37358621-377F76FA-8545-47FE-9F1D-2376278DE0FFQ37358685-58218FA1-8E18-4195-952E-381AA9423A68Q37679773-8632172D-E528-49E9-A77D-2906FB8B822DQ38152788-777A148D-0326-419B-B90D-DE618EC001C1Q38213373-E8412B6B-7F31-4213-9639-97F7EEA61E81Q38224821-5277E500-4276-47C4-9D01-DFE42BF07E39Q38243206-7C1C9A63-673F-4DA3-A70F-8D32B16DE59FQ38262208-61E9A4A4-73F4-48A6-BBDB-B835D9F98AA1Q38581888-E2B3A6E6-6F23-416E-A801-DB28525428D6Q38770072-C110FD32-D0EB-4FA7-A791-DA560F2EAEB2Q38786540-F0D0B2A3-D0CE-414C-84F2-4B018FC05C98Q38988324-B84E7497-6FDB-4801-B787-99FC7E663B23Q39108163-5706E5FB-5A3F-441F-92F7-F754F4DD84BBQ39321216-93B0523B-07D6-4561-9F01-6FF795283375Q39405904-59ED0B41-0833-4F23-BB7A-2C8096A3A962Q40419592-8CF03AC7-BFA7-4C2B-B9DC-AA6C62249D8CQ40458893-0794F795-32C2-47C2-8D3B-ED7A9779EBE5Q42631255-EC98E2A9-23B7-4512-986F-C658D3F0AC34Q44811254-A504276E-1D11-41A4-8CDE-3DEE469F7DC3Q46275485-6DD24E3B-9A75-461B-9A0F-E6A0921AFB40Q48136256-60C65AEC-D73A-417B-8E29-50C55FBB9291Q50042257-863F74D9-5929-48D4-B31A-51C62577F09AQ53686602-C6A47CD9-05FA-446B-89AA-C98D4F324FFE
P2860
The pharmacokinetics and pharmacodynamics of pulmonary Mycobacterium avium complex disease treatment.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
The pharmacokinetics and pharm ...... ium complex disease treatment.
@en
The pharmacokinetics and pharm ...... ium complex disease treatment.
@nl
type
label
The pharmacokinetics and pharm ...... ium complex disease treatment.
@en
The pharmacokinetics and pharm ...... ium complex disease treatment.
@nl
prefLabel
The pharmacokinetics and pharm ...... ium complex disease treatment.
@en
The pharmacokinetics and pharm ...... ium complex disease treatment.
@nl
P2093
P2860
P1476
The pharmacokinetics and pharm ...... ium complex disease treatment.
@en
P2093
Adrah Levin
Charles A Peloquin
Charles L Daley
Eric F Egelund
Leonid B Heifets
Martin J Boeree
Rob E Aarnoutse
Sarah E Totten
P2860
P304
P356
10.1164/RCCM.201204-0682OC
P407
P577
2012-06-28T00:00:00Z